National Institute of Mental Health
Ideas that could help National Institute of Mental Health
- Non-Hallucinogenic TrkB Allosteric Modulator
A pharmaceutical compound designed as a positive allosteric modulator (PAM) of the TrkB receptor to induce neuroplasticity and antidepressant effects. By avoiding 5-HT2A receptor activation, it aims to provide the therapeutic benefits of psychedelics without the associated hallucinogenic effects.
Why it helps: The discovery of a non-hallucinogenic pathway to neuroplasticity opens new avenues for federally funded research into mood disorders.
- Psychedelic Therapy Protocol & Integration Platform
A clinical SaaS tool that standardizes the manualized psychological preparation, dosing-session monitoring, and post-session integration workflow required in every psychedelic-assisted therapy trial, enabling consistent, auditable delivery at scale.
Why it helps: NIMH funds large-scale psychedelic therapy trials and would benefit from a shared protocol platform enabling cross-site standardization and harmonized real-world evidence collection.